3-aminopyrrolidine derivatives as modulators of chemokine...

Details 3-aminopyrrolidine derivatives as modulators of chemokine... 3-aminopyrrolidine derivatives as modulators of chemokine...

2011-07-26

2011-07-26

Loewe, Sun Jae (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S019300, C546S279100

Reexamination Certificate

active

07985730

ABSTRACT:
The present invention relates to 3-aminopyrrolidine derivatives of the formula I:(wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.

REFERENCES:
patent: 4353734 (1982-10-01), Seres et al.
patent: 4785119 (1988-11-01), Hojo et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 6313117 (2001-11-01), Bekkali et al.
patent: 7390830 (2001-11-01), Shiota et al.
patent: 6326372 (2001-12-01), Evans et al.
patent: 6362177 (2002-03-01), Shiota et al.
patent: 6410566 (2002-06-01), Shiota et al.
patent: 6451842 (2002-09-01), Shiota et al.
patent: 7307086 (2007-12-01), Xue et al.
patent: 2002/0094989 (2002-07-01), Hale et al.
patent: 2005/0192302 (2005-09-01), Xue et al.
patent: 2005/0261310 (2005-11-01), Xue et al.
patent: 2006/0004018 (2006-01-01), Xue et al.
patent: 2006/0020133 (2006-01-01), Xue et al.
patent: 2006/0111404 (2006-05-01), Xue et al.
patent: 2007/0149532 (2007-06-01), Xue
patent: 10-298180 (1998-11-01), None
patent: 2004-83511 (2004-03-01), None
patent: 95/08533 (1995-03-01), None
patent: 97/44329 (1997-11-01), None
patent: WO 98/02151 (1998-01-01), None
patent: 98/57641 (1998-12-01), None
patent: 99/25686 (1999-05-01), None
patent: WO 00/05265 (2000-02-01), None
patent: 00/26186 (2000-05-01), None
patent: WO 00/59502 (2000-10-01), None
patent: 00/69432 (2000-11-01), None
patent: 00/69815 (2000-11-01), None
patent: 01/10439 (2001-02-01), None
patent: 01/19816 (2001-03-01), None
patent: 01/28987 (2001-04-01), None
patent: 02/34716 (2002-05-01), None
patent: WO 02/34716 (2002-05-01), None
patent: WO 02/076945 (2002-10-01), None
patent: 03/092586 (2003-11-01), None
patent: 03/093231 (2003-11-01), None
patent: 03/093266 (2003-11-01), None
patent: WO 2004/020584 (2004-03-01), None
patent: 2004/026836 (2004-04-01), None
patent: 2004/041161 (2004-05-01), None
patent: 2004/041163 (2004-05-01), None
patent: 2004/041279 (2004-05-01), None
patent: 2004/041777 (2004-05-01), None
patent: 2004/042351 (2004-05-01), None
patent: 2004/050024 (2004-06-01), None
patent: 2005/044264 (2005-05-01), None
patent: 2005/044795 (2005-05-01), None
patent: 2005/067502 (2005-07-01), None
patent: 2005/070133 (2005-08-01), None
patent: 2005/072361 (2005-08-01), None
patent: WO 2006/073592 (2006-07-01), None
IGA Nephropathy (5 pages), http://kidney.niddk.nih.gov/kudiseases/pubs/iganephropathy/.
Membranoproliferative Glomerulonephritis (4 pages), http://www.clinicaltrials.gov/ct2/show/NCT00275613?term=glomerulonephritis&rank=8.
Incyte CCR2 Antagonist Program (13 pages).
Hot Targets—CCR2 in Inflammatory Disease (7 pages), http://www.pharmaweek.com/Exclusive—Content/1—19.asp.
Collins, Expert Opinion Investig. Drugs 2007, 16(11), 1743-1751.
Examination Report for corresponding European application No. 03790120.4, dated Jul. 16, 2009.
Final Office Action mailed Aug. 19, 2008 in connection with U.S. Appl. No. 11/014,322.
Final Office Action mailed May 30, 2008 in connection with U.S. Appl. No. 11/613,330.
Final Office Action mailed Nov. 2, 2007 in connection with U.S. Appl. No. 11/167,329.
Final Office Action mailed Nov. 21, 2007 in connection with U.S. Appl. No. 11/167,816.
Non-Final Office Action mailed Apr. 1, 2008 in connection with U.S. Appl. No. 11/167,329.
Non-Final Office Action mailed Aug. 22, 2007 in connection with U.S. Appl. No. 11/613,330.
Non-Final Office Action mailed Jan. 17, 2008 in connection with U.S. Appl. No. 11/104,041.
Non-Final Office Action mailed Jul. 24, 2008 in connection with U.S. Appl. No. 11/104,041.
Non-Final Office Action mailed May 16, 2007 in connection with U.S. Appl. No. 11/167,816.
Non-Final Office action mailed May 17, 2007 in connection with U.S. Appl. No. 11/167,329.
Non-Final Office action mailed Oct. 31, 2007 in connection with U.S. Appl. No. 11/014,322.
Notice of Allowance mailed Jun. 25, 2008 in connection with U.S. Appl. No. 11/167,816.
Response to Office Action dated May 6, 2008 in connection with U.S. Appl. No. 11/104,041.
Response to Final Office Action dated Feb. 2, 2008 in connection with U.S. Appl. No. 11/167,329.
Response to Final Office Action dated Mar. 21, 2008 in connection with U.S. Appl. No. 11/167,816.
Response to Non-Final Office Action dated Aug. 16, 2007 in connection with U.S. Appl. No. 11/167,816.
Response to Office Action dated Aug. 16, 2007 in connection with U.S. Appl. No. 11/167,329.
Response to Office Action dated Dec. 6, 2007 in connection with U.S. Appl. No. 11/014,322.
Response to Office Action dated Jan. 22, 2008 in connection with U.S. Appl. No. 11/613,330.
Search Report for corresponding Georgia application No. AP2003008862, dated Jun. 2, 2009.
Search Report for Taiwan application No. 094141007, dated Dec. 23, 2008.
International Preliminary Report on Patentability of the International Searching Authority in International Application No. PCT/US2005/042115, mailed May 22, 2007 (4 pages).
Brodmerkel, C.M., et al., J. Immunol. 2005, 175(8), 5370-8.
Hensley, G.C., et al., J. Med. Chem. (1968), 11, 1034-1037.
Niu Shin et al., “Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2,” Biochemical and Biophysical Research Communications 387 (2009) 251-255.
Weisberg, S. P. et al., “CCR2 modulates inflammatory and metabolic effects of high-fat feeding.”J. Clin. Invest. (2006) 116(1), pp. 115-124; Epub 2005, Dec 8.
Akahoshi et al., “Expression of Monocyte Chemotactic and Activating Factor in Rheumatoid Arthritis,” Arthritis Rheum., 36:762-771 (1993).
Alam et al., “Monocyte Chemotactic and Activating Factor Is a Potent Histamine-releasing Factor for Basophils,” J. Clin. Invest., 89:723-728 (1992).
Allavena et al., “Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3,” Eur. J. Immunol., 24:3233-3236 (1994).
Aukrust et al., “Elevated Circulating Levels of C-C chemokines in Patients With Congestive Heart Failure,” Circulation, 97:1136-1143 (1998).
Baggiolini et al., “Interleukin-8 and Related Chemotactic Cytokines-CXC and CC Chemokines,” and Adv. Immunol., 55:97-179 (1994).
Bischoff et al., “Monocyte Chemotactic Protein 1 Is a Potent Activator of Human Basophils,” J. Exp. Med., 175:1271-1275 (1992).
Boring et al., “Impaired Monocyte Migration and Reduced Type 1 (Th1) Cytokine Responses in C-C Chemokine Receptor 2 Knockout Mice,” J. Clin. Invest., 100:2552-2561 (1997).
Boring et al., “Decreased lesion formation in CCR2 mice reveals a role for chemokines in the initiation of atherosclerosis,” Nature, 394:894-897 (1998).
Butcher, “Leucocyte-Endothelial Cell Recognition: Three (or more) Steps to Specificity and Diversity,” Cell 67:1033-1036 (1991).
Carr et al., “Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant,” Proc. Natl. Acad. Sci. USA, 91:3652-3656 (1994).
Charo et al., “Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails,” Proc. Natl. Acad. Sci. USA, 91:2752-2756 (1994).
Collins et al., “Molecular Rearrangements. XXIII. The Mechanism of Hydride Shift during Hydrolyses of Certain Substituted Norbornyl Tosylates,” J. Am. Chem. Soc. 89:1652-1661 (1967).
Collins et al., “Molecular Rearrangemetns. XXIX. Exo/Endo Stereospecificity of Substituted Classical Norbornyl Cations. A Reassessment of “Hot” Carbonium Ions,” J. Org. Chem. 37:4358-4366 (1972).
Combadier

Affiliated with

Also associated with

Rating

3-aminopyrrolidine derivatives as modulators of chemokine... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3-aminopyrrolidine derivatives as modulators of chemokine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-aminopyrrolidine derivatives as modulators of chemokine... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2727592